Sjögren Syndrome
📧 Sign up to get email alerts when something new happens for Sjögren Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Managed Access Programs for VAY736, Ianalumab
Clinical trial update indicating that managed access programs exist for the investigational antibody ianalumab (VAY736) from Novartis, for p…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's [Phase 2]
Phase 2 clinical trial evaluating subcutaneous Sibeprenlimab in Sjögren's syndrome; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome [Phase 3]
Phase 3 trial evaluating Ianalumab (VAY736) in active Sjögren's syndrome is ongoing but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome [Phase 3]
Clinical Trial Update: A Phase 3, two-arm study to assess the efficacy and safety of Ianalumab (VAY736) in patients with active Sjögren's sy…
-
FDA approval · 2026-03-11FDA Approved: CEVIMELINE HYDROCHLORIDE — Original Application (Zydus Lifesciences Limited)
FDA approves cevimeline hydrochloride as an original ANDA submission from Zydus Lifesciences Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases [Phase 1]
Exploratory Phase 1 clinical trial evaluating YTS109 Cell for relapsed/refractory autoimmune diseases, including systemic lupus erythematosu…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE [Phase 4]
A Phase 4 clinical trial assessing the effectiveness of CO2-laser treatment versus topical promestriene for vaginal dryness in Sjögren's syn…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases [Phase 1]
A Phase 1 exploratory study evaluating the safety and feasibility of YTS109 cell therapy for multiple autoimmune diseases, currently recruit…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases [Phase 1]
Phase 1 trial update on YTS109 cell therapy for relapsed/refractory autoimmune diseases, currently recruiting across multiple indications.
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Penn SICCA Follow-up Study
This update covers a Penn SICCA follow-up clinical trial sponsored by the University of Pennsylvania, investigating dry eye disease and Sjög…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases [Phase 1]
A Phase 1 clinical trial evaluating YTS109 in pediatric relapsed/refractory autoimmune diseases, including SLE and diffuse systemic sclerosi…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases [EARLY_Phase 1]
An early-phase exploratory clinical study evaluating the safety and potential efficacy of an anti-CD19/BCMA U CAR-T cell therapy for relapse…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome [Phase 2]
Open-label extension study assessing the safety of efgartigimod in adults with primary Sjögren's syndrome; the study completed and results w…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases [Phase 1]
A Phase 1 clinical trial of TI-0032-III Injection for relapsed and refractory autoimmune diseases is currently recruiting, encompassing seve…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)
This clinical trial update investigates how quantitative anti-Ro52 antibody analysis may affect prognosis and patient stratification in Sjög…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia [Phase 1]
This entry reports a Phase 1 dose-escalation trial of mesenchymal stromal cells for medical xerostomia, including patients with graft-versus…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE [Phase 2]
A Phase II randomized, double-masked trial is evaluating the safety and efficacy of rhPRG4 for Sjögren's-related dry eye disease and is curr…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
This clinical trial is assessing the medico-economic impact and quality-of-life effects of Sjögren-associated small fiber neuropathy and is …
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases [EARLY_Phase 1]
A Phase 1 targeted CD19 CAR-T therapy trial for autoimmune diseases has been suspended.
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: A Study of RD06-04 in Patients With Active Autoimmune Diseases [EARLY_Phase 1]
A early Phase 1 study of RD06-04 in active autoimmune diseases has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome [Phase 2]
A Phase 2 trial evaluating ESG206, an anti-BAFF-R monoclonal antibody, for Primary Sjögren's syndrome, with the study currently not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. [Phase 2]
A completed Phase 2 study evaluating the mechanism of action of ianalumab in the salivary glands of Sjögren's syndrome patients and its rela…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases [Phase 1]
Phase 1 trial evaluating autologous CD19/BCMA dual-target CAR-T therapy for relapsed/refractory autoimmune diseases; currently recruiting at…
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: Efficacy of Tocilizumab in Primary Sjögren's Syndrome. [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated the efficacy of tocilizumab in patients with Primary Sjögren's syndrome.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity [Phase 3]
An Amgen-sponsored Phase 3 trial evaluating the efficacy and safety of Dazodalibep for Sjögren's syndrome with moderate-to-severe systemic d…